Literature DB >> 35313430

Patient selection for ambulatory laparoscopic cholecystectomy: A systematic review.

Weiwei Chen1, Qiang Wu1, Ning Fu1, Zhiming Yang1, Jingcheng Hao1.   

Abstract

Background: Currently, there is no consensus on patient selection for ambulatory laparoscopic cholecystectomy (LC). This study is a systematic review of previously published patient selection for ambulatory LC.
Methods: A comprehensive search was done in PubMed, Web of Science, Embase and Google Scholar Database up to March 2020 to summarise previously reported medical or surgical selection criteria used for inclusion and exclusion of patients, as well as successful same-day discharge rates and readmission rate after discharge.
Results: Fifty-nine studies with a total of 13,219 patients were included in this systematic review. In total, the median same-day discharge rate was 90% (range: 63%-99.4%), and median readmission rate was 2.22% (range: 0%-16.9%). The most considered medical criteria were American Society of Anesthesiologists classification I and II, age <70, and body mass index <35. Surgical criteria varied greatly. The top three accessible exclusion variables were (1) common bile duct stones, cholangitis, or jaundice (27 publications, 45.8%); (2) history of abdominal surgery (12 publications, 20.3%) and (3) history of pancreatitis (9 publications, 15.3%).
Conclusion: The results of the current study showed the variable patient selection in different centres, the medical aspect criteria may be expanded under adequate pre-anaesthetic assessment and preparation and the surgical aspect criteria should include more laboratory or imaging parameters to ensure the surgical safety.

Entities:  

Keywords:  Ambulatory surgical procedures; laparoscopic cholecystectomy; systematic review

Year:  2022        PMID: 35313430      PMCID: PMC8973487          DOI: 10.4103/jmas.jmas_255_21

Source DB:  PubMed          Journal:  J Minim Access Surg        ISSN: 1998-3921            Impact factor:   1.407


INTRODUCTION

Laparoscopic cholecystectomy (LC) is the most used surgical procedure for symptomatic gallstones globally.[1] In comparison with open surgery, LC has been extensively accepted for its advantages of less invasiveness, post-operative pain, hospitalisation and recovery time.[2345] In the early 1990s, some surgeons introduced the safety and feasibility of the performing of LC in ambulatory settings.[67] Until now, ambulatory LC has not been extensively accepted, especially in developing regions. The main reticence is the concern of possible misdetection of the appearance of any vital complications during the post-operative period. Therefore, basic principles are necessary for determining the ambulatory process and ensuring the highest probability of success with the utmost safety for candidate patients. Nevertheless, currently, there are still no widely recognised patient selection criteria for ambulatory LC in the surgical community. We conducted this systematic review to summarise previously reported selection criteria for ambulatory LC.

METHODS

Following the PRISMA guidelines, a comprehensive search was done in PubMed, Web of Science, Embase and Google Scholar Database up to March 2020 for all accessible publications to summarise the previously reported patient's selection criteria for ambulatory LC. We used the search terms (“Cholecystectomy, Laparoscopic” [Mesh] AND “Ambulatory Surgical Procedures”[Mesh]) to identify all potential records. We also included extra studies in relevant references. Following exclusion criteria were used: (1) published not in English; (2) not original research; (3) paediatric studies; (4) research in other topics, such as nursing, anaesthesiology or ecology; (5) full-text unavailable; and (6) no patient's selection criteria provided. The PRISMA flow chart is presented in Figure 1.
Figure 1

PRISMA flow diagram for literature inclusion

PRISMA flow diagram for literature inclusion After the stepwise exclusion investigation, from all available publications, we extracted the following data: the author's name, study regions, publication years, sample size, successful same-day discharge rates, readmission rate after discharge and medical or surgical selection criteria used for the inclusion and exclusion of patients.

RESULTS

As demonstrated in Figure 1, 290 potentially available publications were included following the identification and implementation strategies. Two hundred and thirty-one records were excluded per the exclusion criteria listed in Figure 1. Eventually, 59 studies were included in this systematic review. Altogether, the patient's selection criteria were provided in 59 publications, including 13219 patients. Most of the studies were performed in Europe and the Americas. In contrast, only ten studies, including 1444 patients, were analysed in the Asian area. The majority of the studies were published from 2000 to 2009 [Figure 2]. In total, the median same-day discharge rate was 90% (range: 63%–99.4%), and median readmission rate was 2.22% (range: 0%–16.9%).
Figure 2

Geographical (a) and temporal distributions (b) of included publications

Geographical (a) and temporal distributions (b) of included publications Regarding the medical factors, the American Society of Anesthesiologists (ASA) Physical Status Classification was the most popular variable to identify the suitability of candidate patients (48 publications, 81.4%). Of the 48 publications that used the ASA classification, most (34 publications, 70.8%) restricted the candidate patients within ASA I and II; 14 studies relaxed the criteria to ASA III [Figure 3]. Age was also usually considered; 28 (47.5%) articles had the limitations of age, but only 19 of them defined the upper age limit; others just required the patients to be adults. Sixty-five and seventy were frequently adopted in most articles [Figure 3]. Twenty-seven (45.8%) studies clearly stated that the common bile duct (CBD) should be in absolute normal status in pre-operative evaluations. Twenty-four (40.7%) studies excluded the patients with ongoing or previous acute cholecystitis. In contrast, some research did not consider acute cholecystitis as a limiting factor. Body mass index (BMI) was also commonlypted for selection in 13 articles, and three other studies avoided obese patients by weight only. In the 13 studies that used BMI, 35 was the common cut-off value [Figure 3].
Figure 3

American Society of Anaesthesiologists classification (a), age upper limit (b), and Body mass index (c) cut-off values used in previous publications

American Society of Anaesthesiologists classification (a), age upper limit (b), and Body mass index (c) cut-off values used in previous publications Concerning the surgical factors, the top three accessible exclusion variables were (1) CBD stones, cholangitis or jaundice (27 publications, 45.8%); (2) history of abdominal surgery (12 publications, 20.3%) and (3) history of pancreatitis (9 publications, 15.3%). All detailed information was summarised in Supplementary Table 1.
Supplementary Table 1

Detailed selection criteria extracted from 59 included publications

Author and yearsRegionPatients numberSelection criteriaDischarge rate (%)Readmission rate (%)
Qu et al. (2019)[1]China42ASA ≤ SAn 18 <age <50, BMI <30, no AC, no atrophic cholecystitis, no intrahepatic gallbladder, no previous abdominal surgery, no cardiopulmonary comorbidities, no diabetes97.60
Gregori et al. (2018)[2]Italy730No cardiopulmonary comorbidities85.73.4
Abet et al. (2017)[3]France102ASA ≤ SA, age ≥ ge, no choledocholithiasis, no substance abuse, no antecedents of gastro-duodenal ulcers, no immune suppression, no need of analgesics, no ongoing pregnancy. No conversion to open98.03.2
Tandon et al. (2016)[4]UK571ASA ≤ SAI78.011.7
Mattila et al. (2015)[5]Finland169ASA ≤ SA, 18 <age <65, BMI <35, no AC, no choledocholithiasis, no previous abdominal surgery, no NSAIDs allergy. No previous pancreatitis. Normal liver function tests87.04.0
Al-Qahtani et al.[6]Kingdom of Saudi Arabia487ASA ≤ SA, AGE ≥ GE, BMI <35, no AC, no thickening gallbladder wall, no previous abdominal surgery, normal liver function tests. Normal liver function test, no thickening gallbladder wall, no insulin-dependent diabetes or epilepsy, no ongoing pregnancy, no upper respiratory tract infection, or uncontrolled hypertension95.0n.a.
Salleh et al. (2015)[7]Malaysia29ASA ≤ SA, age <75, BMI <30, no AC, no chronic cholecystitis, no choledocholithiasis, no thickening gallbladder wall. No dilated CBDn.a.n.a.
Brescia et al. (2013)[8]Italy400ASA ≤ SA, age <70, BMI <35, no AC, no atrophic cholecystitis, no choledocholithiasis. No previous jaundice, mental healthy96.7n.a.
Gelmini et al. (2013)[9]Italy43ASA ≤ SAl 18 <age <70, BMI <35, no AC, no choledocholithiasis, no previous abdominal surgery, no coagulopathy86.12.3
Khan et al. (2012)[10]Bangladesh210ASA ≤ SA, no choledocholithiasis, no morbid obesity97.60
Seleem et al. (2011)[11]Egypt210ASA ≤ SA, no AC, no conversion to openn.a.n.a.
Akoh et al. (2011)[12]UK258ASA ≤ SAI, no AC, no choledocholithiasis69.05.0
Briggs et al. (2009)[13]UK106ASA ≤ SA, BMI <38, no choledocholithiasis, no previous abdominal surgery, no previous ERCP, no previous PNOV84.01.8
Lledó et al. (2008)[14]Spain410ASA ≤ SAI, no choledocholithiasis89.81.5
Chang and Tan (2008)[15]Singapore50Normal liver function tests92.44.0
Psaila et al. (2008)[16]UK176Weight >120 kg, no asthmatic, no NSAIDs allergy85.84.0
Bona et al. (2007)[17]Italy250ASA ≤ SAI, age >18, no choledocholithiasis82.4n.a.
Rathore et al. (2007)[18]UK164ASA ≤ SAI, no choledocholithiasis, no previous pancreatitis, normal-sized CBD86.03.6
Proske et al. (2007)[19]France211ASA ≤ SA, age <75, no coagulopathy, no sleep apnea82.00
Topal et al. (2007)[20]Belgium117ASA ≤ SA, 16 <age <75, no AC, no choledocholithiasis, no coagulopathy94.04.3
Victorzon et al. (2007)[21]Finland567ASA ≤ SA, BMI <3563.02.0
Sherigar et al. (2006)[22]UK198ASA ≤ SAI, no AC, no previous abdominal surgery88.42.0
Kasem et al. (2006)[23]UK150ASA ≤ SA, BMI <35, blood pressure <160/90 mmHg, no previous abdominal surgery, normal liver function tests, no previous anaesthetic complications, no previous difficult intubation. no previous severe AC99.40
Metcalfe et al. (2006)[24]Australia33ASA ≤ SAtrage >1875.86.1
Johansson et al. (2006)[25]Sweden52ASA ≤ SAd 18 <age <70, no AC, no choledocholithiasis, no previous abdominal surgery, no previous pancreatitis92.00
Kaman et al. (2005)[26]India106ASA ≤ SA, age <7095.2n.a.
Jain et al. (2005)[27]UK269ASA ≤ SA, BMI <3295.02.0
Chok et al. (2004)[28]Hong Kong, China73ASA ≤ SAg age <7088.02.7
Vuilleumier and Halkic (2004)[29]Switzerland136ASA ≤ SA, no previous jaundice, no anaesthetic contraindication98.0n.a.
Fassiadis et al. (2004)[30]UK100ASA ≤ SA, age <70, no AC, no morbid obesity, normal liver function tests99.01.0
Skattum et al. (2004)[31]Norway1060ASA ≤ SA0, mental health, no AC, no cholangitis, no pancreatitis92.96.6
Leeder et al. (2004)[32]UK154BMI <40, no cardiopulmonary comorbidity85.70.7
Ammori et al. (2003)[33]UK140ASA ≤ SA, 18 <age <75, no morbid obesity, no AC, no thickening gallbladder wall, no choledocholithiasis, no previous abdominal surgery, no previous constipation or abdominal pain84.01.4
Bal et al. (2003)[34]India313ASA ≤ SA, age <65, mental health92.03.0
Blatt and Chen (2003)[35]Australia41ASA ≤ Sat80.02.4
Maggiore (2002)[36]Italy71ASA ≤ SAly age <75, no gallbladder neoplasia88.716.9
Lau and Brooks (2002)[37]US200ASA ≤ SA, no adverse anaesthetic history, no significant comorbidities, operation time <90 min, no uncorrectable coagulopathy and diffuse intraperitoneal sepsis95.53.0
Lau and Brooks (2002)[38]US888ASA ≤ SA, no adverse anaesthetic history, no significant comorbidities, operation time <90 min96.8n.a.
Curet et al. (2002)[39]US43Age >18, no AC, mental healthy86.00
Siu et al. (2001)[40]Hong Kong, China60ASA ≤ SA, no choledocholithiasis, no thickening gallbladder wall, no contracted gallbladder. No previous AC, abdominal surgery, cholangitis, or pancreatitis90.01.7
Lau and Brooks (2001)[41]US731ASA ≤ SA, no adverse anaesthetic history, no significant comorbidities, operation time <90 min96.6n.a.
Bringman et al. (2001)[42]Sweden100ASA ≤ SA, no previous choledocholithiasis or pancreatitis, normal liver function tests. No CBD dilatation88.0n.a.
Richardson et al. (2001)[43]US847ASA ≤ SAI, not extremely age76.04.0
Young and Connell (2001)[44]Australia14ASA ≤ SAtrage <5095.0n.a.
Fleming et al. (2000)[45]Australia45ASA ≤ SAtrno choledocholithiasis, no coagulopathy, no previous jaundice or pancreatitis. No CBD dilatation82.32.2
Voyles and Boyd (1999)[46]US100Age <65, normal liver enzymes, CBD diameter ≤ 5 mm74.0n.a.
Hollington et al. (1999)[47]Australia67ASA ≤ SAtrano previous abdominal surgery89.63.0
Kumar et al. (1999)[48]India74ASA ≤ SAiaage <6592.05.4
Fleisher et al. (1999)[49]US96ASA ≤ SA999age >1896.9n.a.
Keulemans et al. (1998)[50]Netherlands40ASA ≤ SAheage ≤ geheno AC, no choledocholithiasis, no calcified gallbladder, no previous abdominal surgery92.00
Voitk (1997)[51]Canada85ASA III and IV, or age >7072.08.2
430ASA I and II, and age <7088.02.0
Voyles and Berch (1997)[52]US605Age <65, no choledocholithiasis, no previous abdominal surgery92.0-98.00.2
Narain and DeMaria (1997)[53]US60ASA ≤ SA97no common bile duct dilatation, coagulopathy, pregnancy, or cirrhosis97.05.0
Mjåland et al. (1997)[54]Norway200ASA ≤ SAI, mental health94.08.0
Lam et al. (1997)[55]US213No AC, no clinically significant pain, normal leukocyte count, normal liver function test, no cardiopulmonary comorbidities97.0n.a.
Singleton et al. (1996)[56]Australia40ASA ≤ SAtrano previous surgery, cholecystitis, jaundice, or pancreatitis82.5n.a.
Smith et al. (1994)[57]Canada98No elderly, no significant commodities80.61.0
Farha et al. (1994)[58]US55No AC, no jaundice, CBD diameter <1 cm, no cardiopulmonary comorbidities90.01.8
Stephensona et al. (1993)[59]UK15ASA ≤ SA99age <70, BMI <35, no AC, no chronic cholecystitis. No previous jaundice. Mental healthy80.0n.a.

n.a.: Not available, ASA: American society of anesthesiologist physical status classification, BMI: Body mass index, AC: Acute cholecystitis, CBD: Common bile duct, UK: The United Kingdom, US: The United States, NSAIDs: Nonsteroidal anti-inflammatory drugs, ERCP: Endoscopic retrograde cholangiopancreatography, PONV: Postoperative nausea and vomiting

Detailed selection criteria extracted from 59 included publications n.a.: Not available, ASA: American society of anesthesiologist physical status classification, BMI: Body mass index, AC: Acute cholecystitis, CBD: Common bile duct, UK: The United Kingdom, US: The United States, NSAIDs: Nonsteroidal anti-inflammatory drugs, ERCP: Endoscopic retrograde cholangiopancreatography, PONV: Postoperative nausea and vomiting

DISCUSSION

As per the suggested guidelines from the British Association of Day Surgery in 2019, the patient's selection criteria should fall into three major aspects: social, medical and surgical.[8] The present study summarised all previously reported medical or surgical selection criteria used for ambulatory LC. Regarding the medical aspect, ASA grading, age and BMI are the three most considered variables in previous publications. With the development of modern anaesthesiology, higher ASA and age seem to carry no increased risk of post-operative risk.[910] In 1997, Voitk also reported that ambulatory cholecystectomy is safe for the high-risk patient (ASA III and IV, or age >70).[11] Recently, Gregori et al. proved the safety of ambulatory LC in obese patients with a similar outcome in non-obese patients.[12] The British Association of Day Surgery also suggested that obesity itself is not a contraindication to the ambulatory procedure.[8] In addition, obese patients may even benefit from early mobilisation in the ambulatory procedure.[1314] Thus, we may suggest that, with adequate pre-anaesthetic assessment and preparation, elder or obese patients with stable medical conditions could be considered as candidates for ambulatory LC. More evidence for this opinion is needed. In the surgical aspect, the patients with a high risk of severe post-operative complications should be excluded. Even though LC has experienced four decades of development, the difficulty of LC varies greatly, mainly depending on the inflammation degree of the gallbladder and the anatomy of the Calot's triangle.[15] Inadequate pre-operative evaluation often leads the serious complications such as iatrogenic bile duct injuries and post-operative bleeding. Hence, we highly suggest that the candidate patient should be carefully evaluated regarding the gallbladder inflammation and potential anatomical variation. According to our review, many researchers excluded the patients with acute cholecystitis, history of pancreatitis or abdominal surgery or clinical suspicion of CBD stones.[1617181920212223] In contrast, some other studies also reported acceptable outcomes with those patients.[2425262728] Besides, abnormal laboratory tests, as well as thickening gallbladder wall in ultrasonography has been well known to be risk factors predicting complex operation.[29303132] However, only a few studies considered them as patient's selection criteria.[333435] We, therefore, propose more studies to validate the efficiency of these quantitative and objective parameters in patient selection. In addition, the intraoperative situation should also be considered for the timely interruption of the ambulatory procedure. Previous studies have shown that prolonged operation could predict the inabilities of ambulatory discharge.[3637] Thus, we recommended that unexpected difficult operation should be considered as an exclusion criterion.

CONCLUSION

The results of the current study showed the variable patient selection in different centres, the medical aspect criteria may be expanded under adequate pre-anaesthetic assessment and preparation and the surgical aspect criteria should include more laboratory or imaging parameters to ensure surgical safety.

Financial support and sponsorship

Institutional Research Funding of The First Affiliated Hospital of Chengdu Medical College (CYFY-GQ20).

Conflicts of interest

There are no conflicts of interest.
  77 in total

1.  Selection criteria for laparoscopic cholecystectomy in an ambulatory care setting.

Authors:  C R Voyles; B R Berch
Journal:  Surg Endosc       Date:  1997-12       Impact factor: 4.584

2.  Is laparoscopic cholecystectomy safe and acceptable as a day case procedure?

Authors:  Abdul Kasem; Andrew Paix; Starlene Grandy-Smith; Shamsi El-Hasani
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2006-08       Impact factor: 1.878

3.  Outpatient laparoscopic cholecystectomy in Hong Kong Chinese -- an outcome analysis.

Authors:  Kenneth Siu Ho Chok; Wai Key Yuen; Hung Lau; Francis Lee; Sheung Tat Fan
Journal:  Asian J Surg       Date:  2004-10       Impact factor: 2.767

4.  Contemporary outcomes of ambulatory laparoscopic cholecystectomy in a major teaching hospital.

Authors:  Hung Lau; David C Brooks
Journal:  World J Surg       Date:  2002-06-24       Impact factor: 3.352

5.  Outcome of ASA III patients undergoing day case surgery.

Authors:  G L Ansell; J E Montgomery
Journal:  Br J Anaesth       Date:  2004-01       Impact factor: 9.166

6.  Routine day-case laparoscopic cholecystectomy.

Authors:  P C Leeder; T Matthews; K Krzeminska; T C B Dehn
Journal:  Br J Surg       Date:  2004-03       Impact factor: 6.939

7.  Laparoscopic cholecystectomy in a freestanding outpatient surgery center.

Authors:  G J Farha; B P Green; R L Beamer
Journal:  J Laparoendosc Surg       Date:  1994-10

8.  Introduction of a day-case laparoscopic cholecystectomy service in the UK: a critical analysis of factors influencing same-day discharge and contact with primary care providers.

Authors:  C D Briggs; G B Irving; C D Mann; A Cresswell; L Englert; M Peterson; I C Cameron
Journal:  Ann R Coll Surg Engl       Date:  2009-06-25       Impact factor: 1.891

9.  Laparoscopic cholecystectomy as a day surgery procedure: is it safe?--an egyptian experience.

Authors:  Mohamed I Seleem; Shawkat S Gerges; Khalid S Shreif; Ashref E Ahmed; Ahmed Ragab
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

10.  Outcome and patient acceptance of outpatient laparoscopic cholecystectomy.

Authors:  Nicholas Fassiadis; Litha Pepas; Starlene Grandy-Smith; Andrew Paix; Shamsi El-Hasani
Journal:  JSLS       Date:  2004 Jul-Sep       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.